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Summary 
The liver contributes to immune surveillance against pathogens entering via the gut 
and is itself influenced by alterations in mucosal immune responses and the 
microbiome. Mucosal immunity is also implicated in autoimmune liver diseases that 
associate with inflammatory bowel disease (IBD), and in steatohepatitis where 
compromised enteric barrier function and altered bacterial sensing drive liver 
inflammation. In this article, we discuss recent advances in our understandings of how 
dysregulated mucosal immune responses result in hepatobiliary injury; specifically 
through defective intestinal barrier function, changes in the enteric microbiome and 
loss of immune tolerance, and via shared leucocyte recruitment pathways. 
 
Dysregulated epithelial integrity and enteric dysbiosis 
The intestinal and biliary epithelia are continuous, sharing many properties including 
expression of tight junction proteins such as E-Cadherin, pattern recognition receptors 
(PRR), and an ability to release secretory IgA. The intestinal epithelial barrier does 
not, however, completely impede luminal antigens from entering tissues, although 
penetration beyond the gut is typically restricted by local immunity. In particular, the 
sub-epithelial lamina propria (LP) contains numerous antigen-presenting dendritic 
cells (DC) that sample and process commensal and pathogenic bacteria from within 
the lumen. DC subsequently migrate to draining mesenteric lymph nodes (MLNs) or 
Peyer's patches in order to prime naïve T-cells with gut-tropism. Ordinarily, enteric 
commensals and pathogens are confined to the gut by MLN; however, in the presence 
of intestinal inflammation and increased permeability, live enteric bacteria can be 
detected in the liver where they are contained by the local action of Kupffer cells. 
Thus, the liver functions as second “firewall” that clears commensals from the 
circulation if intestinal defences are overwhelmed [1]. In the presence of liver 
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dysfunction this second firewall fails, leading to bacteria in the systemic circulation 
and sepsis associated with liver failure. Furthermore, onset of portal hypertension may 
result in congestion and oedema of the intestine, thereby enhancing passage of 
microbes beyond the gut lumen, contributing to spontaneous peritonitis and 
bacteraemia. 
 
Intestinal CX3CR1+ macrophages are another critical component of the intestinal 
barrier. These cells use toll-like receptors (TLR) to sense micro-organisms and 
activate innate lymphoid cells to secrete IL-22, which directly promotes epithelial 
integrity and repair [2]. Deletion of CX3CR1 not only results in increased bacterial 
translocation and susceptibility to colitis, but in a diet-induced model of fatty liver 
disease to steatohepatitis, demonstrating how defects in gut integrity can drive hepatic 
inflammation [3]. 
 
Kupffer cells, hepatic sinusoidal endothelial cells (HSEC) and cholangiocytes all 
express PRR allowing them to respond to gut-derived bacterial products, although 
Kupffer cells are relatively resistant to endotoxin, preventing their perpetual 
activation under normal conditions. However, genetic polymorphisms that reduce the 
threshold for PRR-signalling may allow liver inflammation to occur in response to 
commensal flora; whereas others, for instance fucosyltransferase variants in primary 
sclerosing cholangitis (PSC), result in a divergent microbiome, generation of toxic 
bile acids and liver injury [4]. Dietary changes and gut inflammation can also result in 
enteric dysbiosis. For example, high fat diets skew the phyla ratio between Firmicutes 
and Proteobacteria to Bacteriodes resulting in activation of the inflammasome and 
generation of steatohepatitis in mice [5].  
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Immune activation and impaired tolerance in autoimmune liver disease 
To maintain immune homeostasis, mucosal and hepatic immune responses to 
commensal bacteria and harmless food antigens need to be suppressed. Regulatory T-
cells (Treg) are critical for this, and mice that have defective Treg as a consequence of 
deletion of the IL-2 receptor develop spontaneous colitis and cholangitis. This is of 
direct clinical relevance because in PSC, IL-2 receptor polymorphisms associate with 
reduced numbers of functional Treg [6].  
 
Enteric dysbiosis can result in exacerbated pro-inflammatory immune responses, 
wherein microbiota-induced Treg expressing the nuclear hormone receptor RORγt 
actively differentiate into Th17 cells [7]. Notably, autoimmune liver diseases are 
characterised by heightened Th17 responses to pathogens, and polymorphisms in 
CARD9 and REL, both of which are implicated in Th17 differentiation, are associated 
with PSC [4]. IL-17-producing cells are abundant in the liver and intestine. In the gut, 
they are maintained by commensal bacteria which induce innate lymphoid cells to 
secrete IL-22 that in turn stimulates epithelial secretion of serum amyloid A; a critical 
factor for IL-17A expression in T-cells [8]. In both compartments IL-17-secreting T-
cells express the lectin receptor CD161 [9], and use CCR6 to respond to CCL20 
expressed by intestinal and biliary epithelium [10]. Primary biliary cirrhosis is 
associated with genetic variants of CCL20 providing further evidence for the role of 
mucosal immunity in immune-mediated bile duct damage [11].  
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Mucosal lymphocyte recruitment in PSC 
Mucosal lymphocytes are characterised by the expression of molecules associated 
with gut tropism, specifically the integrin α4β7 and chemokine receptor CCR9, that 
become imprinted by intestinal DC in a process dependent on retinoic acid [4]. 
Mucosal lymphocytes are compartmentalised to the gut by their ability to respond to 
gut-selective endothelial adhesion molecules and chemokines; the most important of 
which are mucosal addressin cell-adhesion molecule-1 (MAdCAM-1) and CCL25. 
Normally these molecules are absent from the liver but under certain inflammatory 
conditions they are detected on hepatic endothelium promoting the aberrant 
recruitment of gut-derived α4β7+CCR9+ effector lymphocytes. These effector cells 
can then exploit CCR6 to localise to biliary epithelium, where they drive liver injury 
[4]. 
 
Hepatic expression of MAdCAM-1 is partially regulated through vascular adhesion 
protein (VAP)-1, an ectoenzyme and endothelial adhesion molecule expressed in the 
liver. VAP-1 deaminates primary amines, perhaps those generated in the gut by 
bacteria dominating the microbiome in PSC, producing catabolites that drive NFkB-
dependent endothelial expression of MAdCAM-1 required for the recruitment of 
mucosal lymphocytes [4]. Thus, we can propose a model that brings together 
defective gut barrier function, nutrients, dysbiosis and aberrant lymphocyte homing to 
explain the link between IBD and liver disease (Figure 1). This model has therapeutic 
implications because if correct, drugs targeting CCR9, MAdCAM-1 or α4β7 for the 
treatment of Crohn’s disease and ulcerative colitis could also be effective for IBD-
associated liver diseases. 
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Figure 1: Gut-Liver Immunity in Primary Sclerosing Cholangitis (PSC) 
 [Top Panel] In a genetically predisposed individual, alterations in the gut 
microbiome [A], or abnormal handling of commensal species through epithelial 
pattern recognition receptor (PRR) defects [B] may result in heightened innate 
immune activation as well as toxic bile acid transformations [C]. Naïve lymphocytes, 
imprinted with gut-tropism by intestinal dendritic cells (DC) [D], localise within the 
intestinal mucosa via MAdCAM-1/α4β7 and CCL25/CCR9 dependent mechanisms. 
Effector (as opposed to regulatory) T-cell responses predominate in IBD [E] driving 
intestinal inflammation leading to a defective epithelial barrier [F], exacerbated by the 
loss of protective macrophage populations [G]. 
[Middle Panel] As a consequence of intestinal inflammation enteric pathogens 
translocate beyond the mucosal barrier to the portal circulation and liver where they 
can drive local inflammation via PPR activation [H]. Mucosal effector lymphocytes 
bearing a 'gut-tropic' phenotype are recruited in response to hepatic endothelial 
expression of CCL25 and MAdCAM-1 [I] together with effector cells primed locally 
[J]. The adhesion molecule and ectoenzyme VAP-1 is upregulated during chronic 
inflammation and supports both lymphocyte adhesion directly [K] and catabolises 
amine substrates secreted by gut bacteria resulting in upregulation of several 
endothelial adhesion molecules, including MAdCAM-1, on sinusoidal endothelium 
[L]. Recruited effector cells overwhelm local regulatory networks (M).  
[Bottom Panel] After entering the liver, effector cells use chemokine receptors such 
as CCR6 to respond to chemokines secreted by epithelial target cells (hepatocytes [N] 
or biliary epithelium [O]) resulting in cell-mediated immunological attack and bile 
duct destruction. Hepatobiliary damage is likely to be enhanced through the action of 
toxic bile acids and heightened PRR activation. 
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